Isomorphic Labs Limited

The UK is a global leader in TechBio, drawing substantial investments and nurturing a vibrant ecosystem of talent and businesses, reveals a report launched today by the BIA.

Attending the BIA’s TechBio UK conference this year offered an incredible opportunity to witness the ingenuity and innovation driving the future of life sciences.

President Trump’s “Liberation Day” announcement on April 2 could disrupt biotech, with BIO’s survey showing 90% of U.S. biotech firms relying on imports for FDA-approved products. In addition, news from the mRNA vaccine progress, new lab spaces and Innovate UK’s new leadership.

In this blog, Dr Emma Lawrence, Senior Policy and Public Affairs Manager, BIA, shares more about the launch of our new inaugural Data, AI and Genomics Advisory Committee, a key initiative to support the growing techbio community in the UK.

We are excited to welcome the newly elected members of the BIA Board of Directors, who will bring fresh insights and expertise to help drive our mission forward. Nick Gardiner shares his perspective on the importance of these appointments and the unique value each new Director brings to the BIA.

In this week’s blog, HM Treasury considers ISA changes to enable tax support for growth, a new engineering biology regulatory group gives the UK a strategic edge and a key MHRA webinar on ILAP is upcoming.

This week our new BIA UK biotech financing report shows £3.5 billion invested in 2024, I detail the launch of the STVC Fellowship, look at the impact of the proposed US withdrawal from WHO, and news from Davos on groundbreaking AI-driven drug trials by Isomorphic Labs.

In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

In my final summer update as BIA CEO, I reflect on 12 amazing years and look ahead to my new role as Executive Chair of the Office for Life Sciences. This week we’ve also published our latest finance report, and we’re hiring - so if you’re looking for your next challenge, now’s the time to join Team BIA.

In a world of uncertainty, Britain’s biotech future looks strong.

Isomorphic Labs has expanded its strategic collaboration with Novartis, adding up to three new research programs to accelerate AI-driven drug discovery. This deepened partnership underscores the transformative potential of AI in tackling some of the most challenging targets in medicine.

We are calling on the UK government to mandate pension funds to invest in high-growth UK sectors, as new data from its latest report shows British pension schemes are still missing from the biggest biotech deals. 

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline.